Journal Reviews

PIRADS-3 lesions and clinically significant prostate cancer – what are we missing?

5 December 2022 | | Urologic Oncology | MRI, biopsy, fusion biopsies, prostate cancer, radical prostatectomy, risk, systematic biopsies, targeted biopsies

The use of pre-biopsy MRI has definitely enhanced our decision making in managing patients with suspected prostate cancer (PCa). There is still uncertainty around the outcomes for patients with PIRADS-3 lesions, with a small but definite risk of missing clinically...